Login to Your Account

CEO Spills Exon-Skipper News: Sarepta DMD Filing Next Year

By Randy Osborne
Staff Writer

Wednesday, July 24, 2013

In Wall Street's view, the outcome of another meeting between the FDA and Sarepta Therapeutics Inc. apparently did not bring enough about the path to a new drug application (NDA) filing for eteplirsen, the exon-skipping therapy for Duchenne muscular dystrophy (DMD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription